Revisiting Bromohexitols as a Novel Class of Microenvironment-Activated Prodrugs for Cancer Therapy

Henrik Johansson, Omar Hussain, Simon J. Allison, Tony V. Robinson, Roger Phillips, Daniel Sejer Pedersen

Research output: Contribution to journalArticle

Abstract

Bromohexitols represent a potent class of DNA-alkylating carbohydrate chemotherapeutics that has been largely ignored over the last decades due to safety concerns. The limited structure−activity relationship data available reveals significant changes in cytotoxicity with even subtle changes in stereochemistry. However, no attempts have been made to improve the therapeutic window by rational drug design or by using a prodrug approach to exploit differences between tumour physiology and healthy tissue, such as acidic extracellular pH and hypoxia. Herein, we report the photochemical synthesis of highly substituted endoperoxides as key precursors for dibromohexitol derivatives and investigate their use as microenvironment-activated prodrugs for targeting cancer cells. One endoperoxide was identified to have a marked increased activity under hypoxic and low pH conditions, indicating that endoperoxides may serve as microenvironment-activated prodrugs.

Original languageEnglish
Pages (from-to)228-235
Number of pages8
JournalChemMedChem
Volume15
Issue number2
Early online date26 Nov 2019
DOIs
Publication statusPublished - 17 Jan 2020

Fingerprint Dive into the research topics of 'Revisiting Bromohexitols as a Novel Class of Microenvironment-Activated Prodrugs for Cancer Therapy'. Together they form a unique fingerprint.

  • Cite this